A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/15/2011	WO2011153815A1 Sialic acid (α-(2→6)-d-aminopyranose derivatives, synthesis methods and uses thereof
12/15/2011	WO2011153814A1 Pyrrolyl substituted dihydroindol-2-one derivatives, preparation methods and uses thereof
12/15/2011	WO2011153712A1 Crystalline form of benzylbenzene sglt2 inhibitor
12/15/2011	WO2011153678A1 Composition containing iridoids and uses thereof
12/15/2011	WO2011153647A1 Pharmaceutical composition with olive extract (hydroxytyrosol) and hop extract (xanthohumol) for intranasal application
12/15/2011	WO2011153588A1 Viral polymerase inhibitors
12/15/2011	WO2011134478A3 Methods of treatment of patients at increased risk of development of ischemic events and compounds hereof
12/15/2011	WO2011133668A3 Methods and compositions for the treatment of cancer
12/15/2011	WO2011133521A3 Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
12/15/2011	WO2011133052A3 Use of the modified polysaccharides for heparin neutralization
12/15/2011	WO2011129549A9 Anticancer drug delivery system using ph-sensitive metal nanoparticles
12/15/2011	WO2011124986A3 Polyol modified aminoglycoside-lipid conjugates
12/15/2011	WO2011123719A3 Use of faah inhibitors for treating abdominal, visceral and pelvic pain
12/15/2011	WO2011123427A9 Treatment of cancer by inhibiting activity or expression of late sv-40 factor
12/15/2011	WO2011121607A3 Rasagiline and its pharmaceutically acceptable salts
12/15/2011	WO2011107466A3 Melt-coated pharmaceutical forms
12/15/2011	WO2011106691A3 Curcumin derivatives
12/15/2011	WO2011106300A3 Anti-angiogenesis therapy for the treatment of ovarian cancer
12/15/2011	WO2011103016A3 Compositions and methods for inhibiting ezh2
12/15/2011	WO2011100325A3 Polymorphs of sunitinib salts
12/15/2011	WO2011100282A3 Imatinib mesylate polymorphs
12/15/2011	WO2011096676A3 Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors
12/15/2011	WO2011094389A3 Cxcr4 antagonists for imaging of cancer and inflammatory disorders
12/15/2011	WO2011094208A3 Methods and pharmaceutical compositions for preventing and treating renal impairment
12/15/2011	WO2011093833A3 Effervescent formulations comprising second generation cephalosporin
12/15/2011	WO2011093832A3 Stable efervescent formulations comprising cefaclor
12/15/2011	WO2011093826A3 Effervescent formulations comprising cefaclor and clavulanic acid as active agents
12/15/2011	WO2011093823A3 Effervescent formulations comprising cefaclor and clavulanic acid
12/15/2011	WO2011091401A9 Treatment of immune disorders using kainate receptor antagonists
12/15/2011	WO2011091065A3 Synthetic nanostructures including nucleic acids and/or other entities
12/15/2011	WO2011056532A3 Bazedoxifene formulations with antioxidants
12/15/2011	WO2011034551A3 Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
12/15/2011	WO2011009903A4 Material system comprising endoperoxide adapting to decomposition, and applications
12/15/2011	WO2011009603A8 Tamper-resistant dosage form for oxidation-sensitive opioids
12/15/2011	WO2010129053A8 Egfr inhibitors and methods of treating disorders
12/15/2011	WO2010109115A9 Anticancer compounds, preparation thereof, and therapeutic use thereof
12/15/2011	US20110307967 TetO-p16 Transgenic Mice
12/15/2011	US20110307076 In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
12/15/2011	US20110307074 Biomaterials for use in methods of bone replacement therapy
12/15/2011	US20110307054 Implant coating with nucleic acids
12/15/2011	US20110306677 Pressure Sensitive Adhesive Composition and Pressure Sensitive Adhesive Tape
12/15/2011	US20110306676 Method and Medicament for Pain Management
12/15/2011	US20110306675 Compositions and methods for inhibiting nf-kb mediated tumorigenicity and adhesion-dependent survival of cancer cells
12/15/2011	US20110306674 Pharmaceutical Combination
12/15/2011	US20110306673 Crystalline forms of (1rs,2rs,6rs)-6-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexane-1,3-diol hydrochloride
12/15/2011	US20110306672 Ceramide-analogous metabolites
12/15/2011	US20110306671 Amide derivatives of ethacrynic acid
12/15/2011	US20110306670 Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them
12/15/2011	US20110306669 Rapid onset and short term modafinil compositions and methods of use thereof
12/15/2011	US20110306668 Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid
12/15/2011	US20110306666 New plant derived seed extract rich in essentially fatty acids derived from salvia hispanica l. seed: composition of matter, manufacturing process and use
12/15/2011	US20110306664 Medical dietary composition for treating neurodegenerative diseases
12/15/2011	US20110306663 Triheptanoin diet for adult polyglucosan body disease (apbd) treatment
12/15/2011	US20110306662 Steroid-Derived Cyclopamine Analogs and Methods for Using the Same in the Prevention or Treatment of Cancer
12/15/2011	US20110306661 Hydrogel contact lens for sustained drug release and drug release method using hydrogel contact lens for sustained drug release
12/15/2011	US20110306660 Liquid cannabinoid formulations
12/15/2011	US20110306659 Olopatadine formulations for topical nasal administration
12/15/2011	US20110306658 Novel compound obtained from gamboge resin, and medical uses of the same
12/15/2011	US20110306655 Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
12/15/2011	US20110306654 Methods for identifying analgesic agents
12/15/2011	US20110306653 Stabilization method of functional nucleic acid
12/15/2011	US20110306652 Compositions and their uses directed to huntingtin
12/15/2011	US20110306651 Rna interference mediating small rna molecules
12/15/2011	US20110306650 Process for the preparation of glycopyrronium chloride
12/15/2011	US20110306649 Prodrugs of ion channel modulating compounds and uses thereof
12/15/2011	US20110306648 Apoptosis inhibitor
12/15/2011	US20110306647 Novel polymorphs of sunitinib malate
12/15/2011	US20110306644 Metalloenzyme inhibitor compounds
12/15/2011	US20110306642 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
12/15/2011	US20110306641 Novel 2,6-substituted-3-nitropyridine derivative, method for preparing same, and pharmaceutical preparation including same
12/15/2011	US20110306640 Dabigatran in tumour therapy
12/15/2011	US20110306638 Benzisoxazole piperidinyl derivatives, pharmaceutical compositions comprising the derivatives and their use
12/15/2011	US20110306637 Modulators of atp-binding cassette transporters
12/15/2011	US20110306636 Oxazole pyridine derivatives useful as s1p1 receptor agonists
12/15/2011	US20110306635 Pyridine compounds as subtype selective modulators of alpha2b and /or alpha 2c adrenergic receptors
12/15/2011	US20110306634 Amorphous Salt of a Macrocyclic Inhibitor of HCV
12/15/2011	US20110306633 Selective m4 receptor antagonist and its medical use
12/15/2011	US20110306632 Solid Dispersions Containing Kinase Inhibitors
12/15/2011	US20110306631 Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases or conditions, or cancer
12/15/2011	US20110306630 Pharmaceutical compositions comprising colloidal silicon dioxide
12/15/2011	US20110306629 Novel c-1 analogs of pancratistatin and 7-deoxypancratistatin and processes for their preparation
12/15/2011	US20110306628 Non-peptidyl, potent, and selective mu opioid receptor antagonists
12/15/2011	US20110306627 Morphinan Compounds
12/15/2011	US20110306626 Imidazolinone derivatives as cgrp receptor antagonists
12/15/2011	US20110306625 Compounds and compositions as protein kinase inhibitors
12/15/2011	US20110306624 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
12/15/2011	US20110306623 Novel compounds comprising a 3-(5-alkoxypyrimidin-2-yl) pyrimidin-4(3h)-one structure and drugs that comprise same
12/15/2011	US20110306622 Methods of treating hematological disorders with quinazolinone compounds in selected subjects
12/15/2011	US20110306621 Acylguanidine derivatives
12/15/2011	US20110306619 6-phenyl-2-[((piperidin-4-ylmethyl)-piperazin-1yl) or piperazin 1-ylmethyl)-piperidin-1-yl)]-imidazo[2,1-b][1,3,4]thiadiazole derivatives and their use
12/15/2011	US20110306618 JNK Modulators
12/15/2011	US20110306616 Novel Compounds as Cannabinoid Receptor Ligands
12/15/2011	US20110306615 Novel imidazolidine derivative and use thereof
12/15/2011	US20110306614 N-Hydroxylsulfonamide Derivatives as New Physiologically Useful Nitroxyl Donors
12/15/2011	US20110306613 Chemical compounds
12/15/2011	US20110306612 Quinazolinone, quinolone and related analogs as sirtuin modulators
12/15/2011	US20110306611 Transcription factor modulating compounds and methods of use thereof
12/15/2011	US20110306610 9-substituted 8-oxoadenine compound
12/15/2011	US20110306609 Thiazolopyridine sirtuin modulating compounds
12/15/2011	US20110306608 Compositions and methods for treating vascular, autoimmune and inflammatory diseases

1 ... 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 ... 7860